Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to
study the effectiveness of combining trastuzumab with flavopiridol in treating patients who
have metastatic breast cancer